Cleo Diagnostics (ASX:COV) Buyback Yield %: -6.63 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:COV Cleo Diagnostics Ltd ASX:COV
14 GF Score
Price A$0.41
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Buyback Yield %?

Cleo Diagnostics ASX:COV -10.00% 14 Buyback Yield % is -6.63 as of Jul. 15, 2026. GuruFocus rates ASX:COV with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 347 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 66.86% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cleo Diagnostics's current buyback yield was -6.63%.

Cleo Diagnostics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Buyback Yield % Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
Buyback Yield %
0.00 -25.56 0.00

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial -53.36 -25.56 0.00 0.00 -5.60

ASX:COV vs ABT, SYK, MDT: Buyback Yield % Comparison

For the Medical Devices subindustry, Cleo Diagnostics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics Buyback Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Buyback Yield % falls into.


ASX:COV
14GF Score
Cleo Diagnostics Ltd ASX:COV
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cleo Diagnostics's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 50.115
=0.00%

Cleo Diagnostics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.373 + 5.009) / 82.80151
=-5.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -6.63 mean?
Cleo Diagnostics (ASX:COV) has a Buyback Yield % of -6.63 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cleo Diagnostics and its competitors. According to the industry distribution chart, Cleo Diagnostics ranks #232 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 66.9%.
Is Cleo Diagnostics' Buyback Yield % too high?
Cleo Diagnostics' current Buyback Yield % is -6.63. Based on the distribution chart, Cleo Diagnostics ranks #232 out of 347 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cleo Diagnostics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #232 out of 347 companies for Buyback Yield %. This places Cleo Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Buyback Yield % is -6.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Buyback Yield % of -6.63. The current Buyback Yield % is -6.63. Cleo Diagnostics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Buyback Yield % is -6.63 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
14GF Score

Get the complete analysis for ASX:COV

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.41
Price